CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL
Conditions: Acute Lymphoblastic Leukemia,B-Cell; Non-hodgkin Lymphoma,B Cell Interventions: Biological: CD19-BAFF Targeted CAR T-cells Sponsors: Zhejiang University; Shanghai YaKe Biotechnology Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Biotechnology | Leukemia | Lymphoma | Non-Hodgkin's Lymphoma | Research